Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermatophagoides allergenic extract is a biological product derived from house dust mites of the genus *Dermatophagoides*, primarily *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by LOFARMA S.p.A., it is utilized for both the diagnosis and treatment of respiratory allergies, such as allergic rhinitis and allergic asthma. The extract functions by interacting with allergen-specific IgE antibodies on the surface of mast cells and basophils; in diagnostic skin prick testing, this interaction triggers the release of inflammatory mediators like histamine. In the context of allergen-specific immunotherapy (AIT), the extract is administered to modulate the patient's immune response, inducing long-term desensitization and immune tolerance. The product has been evaluated in Phase 2 in-vivo biological standardization studies to define its activity in histamine equivalent prick (HEP) units.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dermatophagoides allergenic extract.